ForteBio Inc.

In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracte

Recently, Elsevier Business Intelligence convened a panel of venture capitalists and device company CEOs to discuss the climate for early- and late-stage funding. Their conclusions: there is money out

It's common wisdom within the halls of Big Pharma to look East--especially to China--for future revenue growth as increasing regulatory oversight and reimbursement hurdles in the US and Europe create

A look at medical device and in vitro diagnostics/research financing, M&A, and alliance activity July–September 2008 In this issue, we present a review of medical device and in vitro diagnostics/res